Skip to content

Study · Animal study (in vivo) · mouse and rat · 2013

7 results

Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents.

Chin YP, Keni J, Wan J, Mehta H, Anene F, Jia Y, Lue YH, Swerdloff R, Cobb LJ, Wang C, Cohen P

Endocrinology8 Jul 2013Cited by 55 (Europe PMC)

PMID23836030 (opens in a new tab)PMCIDPMC3776863 (opens in a new tab)DOI10.1210/en.2012-2004 (opens in a new tab)PepBankPUB-23836030
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In wild type mice, HNGF6A gave a longer humanin half-life than HNG.

    In plain wordsIn mice, the humanin analogue HNGF6A stayed in the blood longer than the analogue HNG.

    Peptide
    Humanin
    Outcome
    IncreaseHalf-life of HN in WT mice given HNGF6A
    Study

    mousen: not reported in source

    Comparator
    WT mice treated with HNG
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    WT mice treated with HNGF6A and IGFBP-3(-/-) mice treated with HNG displayed a longer half-life of HN compared with WT mice treated with HNG.
    2 context sentences
    Summary · context
    11-week-old male IGFBP-3(-/-) and wild type (WT) mice were divided into 3 groups: WT mice treated with HNG, WT mice treated with HNGF6A, and IGFBP-3(-/-) mice treated with HNG.
    Summary · context
    Plasma was obtained from mice following ip injection with HN analogues, and HN levels were measured with ELISA.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In IGFBP-3 knockout mice, HNG gave a longer humanin half-life than in wild type mice given HNG.

    In plain wordsIn mice lacking IGFBP-3, the humanin analogue HNG stayed in the blood longer than in normal mice.

    Peptide
    Humanin
    Outcome
    IncreaseHalf-life of HN in IGFBP-3 knockout mice given HNG
    Study

    mousen: not reported in source

    Comparator
    WT mice treated with HNG
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    WT mice treated with HNGF6A and IGFBP-3(-/-) mice treated with HNG displayed a longer half-life of HN compared with WT mice treated with HNG.
    2 context sentences
    Summary · context
    11-week-old male IGFBP-3(-/-) and wild type (WT) mice were divided into 3 groups: WT mice treated with HNG, WT mice treated with HNGF6A, and IGFBP-3(-/-) mice treated with HNG.
    Summary · context
    Plasma was obtained from mice following ip injection with HN analogues, and HN levels were measured with ELISA.
  3. 03AnimalAnimal study (in vivo)Other

    In mice, IGF-1 levels decreased over time following HNG injection.

    In plain wordsIn mice, IGF-1 levels fell over time after an injection of the humanin analogue HNG.

    Peptide
    Humanin
    Outcome
    DecreaseIGF-1 level after HNG
    Study

    mousen: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Following HNG injection, both IGF-1 and IGFBP-3 levels decreased over time.
    2 context sentences
    Summary · context
    11-week-old male IGFBP-3(-/-) and wild type (WT) mice were divided into 3 groups: WT mice treated with HNG, WT mice treated with HNGF6A, and IGFBP-3(-/-) mice treated with HNG.
    Summary · context
    Plasma was obtained from mice following ip injection with HN analogues, and HN levels were measured with ELISA.
  4. 04AnimalAnimal study (in vivo)Other

    In mice, IGFBP-3 levels decreased over time following HNG injection.

    In plain wordsIn mice, IGFBP-3 levels fell over time after an injection of the humanin analogue HNG.

    Peptide
    Humanin
    Outcome
    DecreaseIGFBP-3 level after HNG
    Study

    mousen: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Following HNG injection, both IGF-1 and IGFBP-3 levels decreased over time.
    2 context sentences
    Summary · context
    11-week-old male IGFBP-3(-/-) and wild type (WT) mice were divided into 3 groups: WT mice treated with HNG, WT mice treated with HNGF6A, and IGFBP-3(-/-) mice treated with HNG.
    Summary · context
    Plasma was obtained from mice following ip injection with HN analogues, and HN levels were measured with ELISA.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    The half-life of humanin was longer in rats than in mice.

    In plain wordsThe humanin analogue stayed in the blood longer in rats than in mice.

    Peptide
    Humanin
    Outcome
    IncreaseHalf-life of HN in rats versus mice
    Study

    ratn: not reported in source

    Comparator
    Mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The half-life of HN was found to be longer in rats compared with mice.
    1 context sentence
    Summary · context
    Adult male Sprague Dawley rats were also ip injected with HNG, and HN levels were measured in various tissues (plasma, liver, heart, and brain) by ELISA.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In rats given HNG, humanin levels were highest in plasma and present in liver.

    In plain wordsIn rats, the humanin analogue was found mostly in the blood and also in the liver.

    Peptide
    Humanin
    Outcome
    Not applicableHN levels in plasma and liver of rats
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    In rats, HN levels were found to be highest in plasma, present in liver
    3 context sentences
    Summary · context
    Adult male Sprague Dawley rats were also ip injected with HNG, and HN levels were measured in various tissues (plasma, liver, heart, and brain) by ELISA.
    Summary · context
    11-week-old male IGFBP-3(-/-) and wild type (WT) mice were divided into 3 groups: WT mice treated with HNG, WT mice treated with HNGF6A, and IGFBP-3(-/-) mice treated with HNG.
    Summary · context
    Plasma was obtained from mice following ip injection with HN analogues, and HN levels were measured with ELISA.
  7. 07AnimalAnimal study (in vivo)Pharmacokinetics

    In rats given HNG, humanin was undetectable in brain or heart.

    In plain wordsIn rats, the humanin analogue could not be detected in the brain or heart.

    Peptide
    Humanin
    Outcome
    Not applicableHN levels in brain and heart of rats
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    undetectable in brain or heart.
    3 context sentences
    Summary · context
    Adult male Sprague Dawley rats were also ip injected with HNG, and HN levels were measured in various tissues (plasma, liver, heart, and brain) by ELISA.
    Summary · context
    11-week-old male IGFBP-3(-/-) and wild type (WT) mice were divided into 3 groups: WT mice treated with HNG, WT mice treated with HNGF6A, and IGFBP-3(-/-) mice treated with HNG.
    Summary · context
    Plasma was obtained from mice following ip injection with HN analogues, and HN levels were measured with ELISA.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.